E-Mail
DALLAS, March 11, 2021 Taking the triglyceride-lowering medication icosapent ethyl cut the risk of stroke by an additional 36% in people at increased risk of cardiovascular disease who already have their bad cholesterol levels under control using statin medications, according to preliminary research to be presented at the American Stroke Association’s International Stroke Conference 2021. The virtual meeting is March 17-19, 2021 and is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health.
“Icosapent ethyl is a new way to further reduce the risk of stroke in patients with atherosclerosis or who are at high risk of stroke, who have elevated triglyceride levels and are already taking statins,” said Deepak L. Bhatt, M.D., M.P.H., lead author of the study and executive director of interventional cardiovascular programs at the Brigham and Women’s Hospital Heart & Vascular Center in Boston.
Triglyceride-lowering medication may lower stroke risk in people with heart disease
Taking the triglyceride-lowering medication icosapent ethyl cut the risk of stroke by an additional 36% in people at increased risk of cardiovascular disease who already have their bad cholesterol levels under control using statin medications, according to preliminary research to be presented at the American Stroke Association s International Stroke Conference 2021.
The virtual meeting is March 17-19, 2021 and is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health.
Icosapent ethyl is a new way to further reduce the risk of stroke in patients with atherosclerosis or who are at high risk of stroke, who have elevated triglyceride levels and are already taking statins.
email article
Direct oral anticoagulants (DOACs) are getting used off-label with prosthetic heart valves, even mechanical valves in some cases, a national registry showed.
At least some valve patients were discharged with a DOAC prescription at 78.6% 0f the 1,092 hospitals and by 59.6% of the 2,731 physicians participating in the Society of Thoracic Surgeons Adult Cardiac Surgery Database from July 2014 through June 2017.
For mechanical heart valve recipients, the rate was 1.1% with aortic valve replacement and 1.04% with mitral valve replacement, without significant change over time for either, Ankur Kalra, MD, of the Cleveland Clinic, and colleagues reported in I am really very surprised that DOACs are being used in mechanical heart valves, commented Deepak Bhatt, MD, MPH, of Brigham and Women s Hospital Heart & Vascular Center and Harvard Medical School in Boston, who was not involved with the study.
email article
ST-segment myocardial infarction (STEMI) in COVID-19 patients was linked to a higher burden of neutrophil extracellular traps (NETs) in a case series suggesting an important role in pathogenesis of coronary thrombosis from the infection.
These structures webs spun by neutrophils to snag pathogens turned up in coronary thrombi of all five COVID-positive STEMI patients where thrombus aspiration was done in the cath lab of one Spanish academic center.
The density of NETs was much higher in these samples than in a historical STEMI series of 50 patients, of whom 68% had NETS detected in coronary thrombus aspirates: a median of 61% versus 19% (